AU2009244400B2 - Antiviral cell penetrating peptides - Google Patents

Antiviral cell penetrating peptides Download PDF

Info

Publication number
AU2009244400B2
AU2009244400B2 AU2009244400A AU2009244400A AU2009244400B2 AU 2009244400 B2 AU2009244400 B2 AU 2009244400B2 AU 2009244400 A AU2009244400 A AU 2009244400A AU 2009244400 A AU2009244400 A AU 2009244400A AU 2009244400 B2 AU2009244400 B2 AU 2009244400B2
Authority
AU
Australia
Prior art keywords
amino acids
peptide
nyad
seq
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009244400A
Other languages
English (en)
Other versions
AU2009244400A1 (en
AU2009244400A2 (en
Inventor
Francesca Curreli
Asim Kumar Debnath
Hongtao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Publication of AU2009244400A1 publication Critical patent/AU2009244400A1/en
Publication of AU2009244400A2 publication Critical patent/AU2009244400A2/en
Application granted granted Critical
Publication of AU2009244400B2 publication Critical patent/AU2009244400B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2009244400A 2008-05-06 2009-05-05 Antiviral cell penetrating peptides Ceased AU2009244400B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5095508P 2008-05-06 2008-05-06
US61/050,955 2008-05-06
PCT/US2009/042913 WO2009137532A1 (en) 2008-05-06 2009-05-05 Antiviral cell penetrating peptides

Publications (3)

Publication Number Publication Date
AU2009244400A1 AU2009244400A1 (en) 2009-11-12
AU2009244400A2 AU2009244400A2 (en) 2010-11-11
AU2009244400B2 true AU2009244400B2 (en) 2012-12-20

Family

ID=40957984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009244400A Ceased AU2009244400B2 (en) 2008-05-06 2009-05-05 Antiviral cell penetrating peptides

Country Status (6)

Country Link
US (2) US8324153B2 (enExample)
EP (1) EP2283033A1 (enExample)
JP (1) JP2011522796A (enExample)
AU (1) AU2009244400B2 (enExample)
CA (1) CA2725227A1 (enExample)
WO (1) WO2009137532A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8940864B2 (en) * 2006-10-05 2015-01-27 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
CA2725227A1 (en) * 2008-05-06 2009-11-12 Asim Kumar Debnath Antiviral cell penetrating peptides
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012137036A1 (en) * 2011-04-04 2012-10-11 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
AU2012249301A1 (en) * 2011-04-29 2013-11-21 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
WO2014053880A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN105622732B (zh) * 2014-10-30 2019-10-25 中国科学院武汉病毒研究所 猴病毒40衣壳蛋白vp1在作为细胞穿膜蛋白中的应用
HRP20191400T1 (hr) 2014-12-24 2019-11-15 Aadigen Llc Peptidi i nanočestice za unutarstaničnu isporuku molekula
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
WO2019118893A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2019157131A1 (en) 2018-02-07 2019-08-15 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
CA3140693A1 (en) 2019-06-07 2020-12-10 Kamlendra Singh Peptide inhibitors for the inhibition of hiv capsid
EP4114431A2 (en) * 2020-03-04 2023-01-11 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized sars-cov-2 peptides and uses thereof
WO2021216845A1 (en) * 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187548B1 (en) 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US6239270B1 (en) 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
ES2187947T5 (es) * 1997-03-10 2014-01-29 Roche Diagnostics Gmbh Procedimiento para la detección simultánea de antígenos de HIV y anticuerpos de HIV
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
WO2000061724A2 (en) 1999-04-09 2000-10-19 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6653102B2 (en) 2000-10-17 2003-11-25 Myriad Genetics, Inc. Nucleic acid encoding a phosphatase 2C that interacts with Fe 65
WO2005044839A2 (en) * 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2008008998A2 (en) 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2008009000A2 (en) 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
EP2061487A4 (en) 2006-09-11 2009-12-02 Univ Illinois MODIFIED CUPREDOXIN-DERIVED PEPTIDES AND METHOD FOR THEIR USE
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
JP5078401B2 (ja) * 2007-03-27 2012-11-21 株式会社Ａｄｅｋａ 防水シート
WO2009042237A2 (en) * 2007-09-26 2009-04-02 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) * 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
CA2725227A1 (en) * 2008-05-06 2009-11-12 Asim Kumar Debnath Antiviral cell penetrating peptides
US20110218155A1 (en) * 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides

Also Published As

Publication number Publication date
CA2725227A1 (en) 2009-11-12
WO2009137532A1 (en) 2009-11-12
JP2011522796A (ja) 2011-08-04
US20130059776A1 (en) 2013-03-07
AU2009244400A1 (en) 2009-11-12
EP2283033A1 (en) 2011-02-16
US20090281041A1 (en) 2009-11-12
US8933019B2 (en) 2015-01-13
US8324153B2 (en) 2012-12-04
AU2009244400A2 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
US8324153B2 (en) Antiviral cell-penetrating peptides
JP2011522796A5 (enExample)
Steckbeck et al. C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic
JP2010505831A (ja) 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド
JP2024531265A (ja) ウイルス膜融合阻害剤を最適化する方法、および広域スペクトルの抗コロナウイルスリポペプチドとその応用
Zhang et al. Dual-acting stapled peptides target both HIV-1 entry and assembly
US9724383B2 (en) Stabilized trimeric HIV-1 GP41 fusion inhibitor polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif
US20080233559A1 (en) Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein
JP2020517741A (ja) Ｈｉｖを強力に阻害するためのリポペプチド、その誘導体、その医薬組成物及びその使用
US8937154B2 (en) Stabilized therapeutic small helical antiviral peptides
EP2291392B1 (en) Bifunctional molecules for inhibiting hiv entry
KR102962154B1 (ko) 바이러스 막 융합 억제제인 광범위 항-코로나바이러스 리포펩티드를 최적화하는 방법 및 그의 용도
CA2766417A1 (en) Stabilized therapeutic small helical antiviral peptides
AU2012200580A1 (en) Stabilized therapeutic small helical antiviral peptides
Bailey The mechanism of HIV-1 virolytic inactivation by Env-targeting peptide triazole thiols
Zhang Interaction-mediating sequences within class I viral fusion glycoproteins: their roles in viral infection and in applications
Simin Interaction-Mediating Sequences within Class I Viral Fusion Glycoproteins: Their Roles in Viral Infection and in Applications
Tien et al. Understanding regulation of HIV-1 protease precursor autoprocessing
WO2005068492A2 (en) Peptide inhibitors of retroviral integrase useful for the treatment of retroviral infection
Poe Bimolecular fluorescence complementation reveals that HIV-1 Nef oligomerization is essential for CD4 downregulation and viral replication
Suntoke HIV entry: a biophysical and mutational analysis of gp41-mediated membrane fusion and its inhibition
Pritchard Architecture of the HIV-1 glycan shield
WO2005113059A2 (en) Disruption of the processing of the viral capsid-spacer peptide 1 protein

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 SEP 2010

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired